FOXP3 and neoplasm: In the studies where we depleted Foxp3+ Tregs, we used Foxp3-GFPDTR transgenic mice and confirmed that the late depletion of Foxp3+ Tregs alone was ineffective (Supplemental Figure 8), but when combined with the E743–77-pulsed bm12 mBMDC vaccine, it significantly enhanced tumor suppression and enhanced the frequency of E7/H2Db tetramer+CD8+ T cells especially in tumors (Figure 6, B–E).